Don't fuel the fire: decreasing intravenous haloperidol use in high risk patients via a customized electronic alert.

Delivering useful clinical decision support to providers who are ordering high risk drugs for high risk patients is imperative for safe pharmacotherapy. This paper presents a focused electronic clinical decision support intervention designed to decrease the risk of corrected QT interval (QTc) related adverse drug events in a high risk patient population. Results showed that a customized alert can both decrease the number of alerts sent to providers while still improving the safety of prescribing practices for intravenous haloperidol. The alert leveraged components of the electronic health record to significantly decrease the rate of inappropriate prescription of intravenous haloperidol in patients with QTc >500 ms from 50% to 14%. The results also suggest providers may abandon the appropriate prescription of a medication in response to an alert. The findings support the necessity of careful targeting of electronic alerts and monitoring for unintended consequences when implementing these types of electronic alerts. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.